PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d8d1bff39dfae3cad180e0 — DOI: https://doi.org/10.1186/bcr2419

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. RB in Breast Cancer: The Crossroads of Tumorigenesis and Treatment· 2007 · 109 citations
2. <i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)· 2002 · 363 citations
3. Expression and amplification of cyclin genes in human breast cancer.· 1993 · 675 citations
4. Cell-cycle targeted therapies· 2003 · 246 citations
5. Control of the cell cycle and apoptosis· 1999 · 215 citations